| |
Veeva Systems today announced that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd, a global biotech company, is using Veeva Vault Validation Management to streamline and accelerate their validation process. By adopting a validation solution with built-in best practices, the company can execute digital validation while centralizing data and improving visibility.
“As the industry continues to shift from traditional paper-based validation, more companies are advancing validation with Veeva Vault Validation Management to streamline and standardize processes,” said Nina Ricciardelli, director, Veeva Vault Validation Management. “SK Life Science, Inc. is a prime example of one of those forward-thinking companies modernizing validation for greater efficiency and speed.”
SK Life Science, Inc. (sklifescienceinc.com), an innovative pharmaceutical company committed to accelerating the development of next-generation treatments for central nervous system (CNS) disorders and cancer care, adopted Vault Validation Management to further support its team with digital collaboration, standardized processes and workflows, and simpler test execution. The company is building off its success with Veeva Vault QualityDocs and Veeva Vault QMS to optimize its validation programs, driving greater compliance and traceability across all systems. Shifting to a digital approach provides the transparency necessary to identify trends and proactively address potential issues, reducing compliance risks.
“Veeva Vault Validation Management allows us to further simplify our validation process for significant cost and time-savings in test execution,” said Hina Patel, vice president and global head of quality assurance, SK Life Science, Inc. “Using an advanced validation solution helps improve our efficiency, data integrity, and audit readiness.”
About Veeva Systems
Veeva (veeva.com) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov/.
|
deivis.mercado[.]veeva.com 
